enGene Therapeutics Inc. (ENGN) Current Ratio
- Current ratio · latest quarter: Value 10.21×; Formula and calculation Current assets / current liabilities..
Current ratio
Overview →Financial period ending 2026-07-31; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Current ratio · latest quarter | 10.21× | Current assets / current liabilities. $277.90M ÷ $27.21M ≈ 10.21× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Current assets | 277.90M USD | Assets, Current |
| Current obligations | 27.21M USD | Liabilities, Current |
| Cash and equivalents | 41.02M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | 225.29M USD | Marketable Securities, Current |
| Customer receivables | (m) | |
| Inventory | (m) | |
| Payables | 2.54M USD | Accounts Payable, Current |
| Borrowing debt due within one year | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Current assets (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory (USD) | Payables (USD) | Borrowing debt due within one year (USD) | Current ratio |
|---|---|---|---|---|---|---|---|---|---|
| 2026-07-31 | $277.90M | $27.21M | $41.02M | $225.29M | (m) | (m) | $2.54M | (m) | 10.21× |
| 2026-04-30 | $270.00M | $21.48M | $29.83M | $228.64M | (m) | (m) | $1.79M | (m) | 12.57× |
| 2026-01-31 | $289.22M | $24.61M | $36.61M | $239.34M | (m) | (m) | $2.44M | (m) | 11.75× |
| 2025-10-31 | $201.39M | $31.98M | $50.15M | $143.58M | (m) | (m) | $6.69M | (m) | 6.30× |
| 2025-07-31 | $211.31M | $20.44M | $32.62M | $169.29M | (m) | (m) | $2.38M | (m) | 10.34× |
| 2025-04-30 | $227.97M | $18.00M | $57.55M | $159.85M | (m) | (m) | $1.57M | (m) | 12.66× |
| 2025-01-31 | $222.32M | $12.96M | $62.35M | $151.47M | (m) | (m) | $2.60M | (m) | 17.16× |
| 2024-10-31 | $247.36M | $14.66M | $173.00M | $65.33M | (m) | (m) | $1.41M | (m) | 16.87× |
| 2024-07-31 | $262.69M | $13.46M | $257.68M | (m) | (m) | (m) | $2.86M | (m) | 19.52× |
| 2024-04-30 | $269.61M | $6.30M | $264.81M | (m) | (m) | (m) | $211.00K | (m) | 42.80× |
| 2024-01-31 | $89.58M | $6.91M | $85.65M | (m) | (m) | (m) | $1.27M | (m) | 12.97× |
| 2023-10-31 | $85.44M | $5.26M | $81.52M | (m) | (m) | (m) | $1.16M | (m) | 16.25× |
| 2022-10-31 | $22.58M | $5.10M | $20.43M | (m) | (m) | (m) | $723.00K | (m) | 4.42× |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B | |
| Caribou Biosciences, Inc. (CRBU) | United States | $0.134B | -1.79 |
| Tenaya Therapeutics, Inc. (TNYA) | United States | $0.140B | -1.60 |
| LENZ Therapeutics, Inc. (LENZ) | United States | $0.117B | -1.41 |
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| Humacyte, Inc. (HUMA) | United States | $0.155B | -2.26 |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |